Fig. 4

The correlation between the type of compound EGFR mutations and patients’ prognosis to first-line EGFR TKIs. A Kaplan–Meier curve of progression-free survival in NSCLC patients in strata of the number of EGFR mutations. B Kaplan–Meier curve of progression-free survival in dual EGFR mutation-positive patients in the strata of the various combination of EGFR mutations. One patient with the common + common subtype was not included in the analysis. C Kaplan–Meier curve of progression-free survival in compound EGFR mutation-positive patients in the strata of various generations of EGFR TKIs. D Kaplan–Meier curve of progression-free survival in compound EGFR mutation-positive patients who harbored EGFR VUSs, and these patients were in the strata of different types of compound EGFR mutations, as well as the location of the VUSs, which can be inside the EGFR kinase domain (KD +) or outside the EGFR kinase domain (KD −). One patient with the rare + VUSs (KD −) subtype was not included in the analysis. Log‐rank test with P-value < 0.05 was considered to be statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001)